Back to results
US 11,697,850 B2Granted
Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment
AssigneesThe Brigham and Women's Hospital, Inc., Celera Corporation
InventorsPaul M. Ridker, Daniel Chasman, Dov Shiffman
Life of this patent
Estimating the term…
Abstract
This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
Claims16
A method comprising:
- (a) determining the identity of a single nucleotide polymorphism at position chromosome 6:160880877 (March 2006 assembly—NCBI build 36.1;
- rs3798220 dbSNP @ NCBI) of an apolipoprotein(a) (Apo(a)) gene in a human subject,
- wherein the presence of cytosine or guanine at position chromosome 6:160880877 indicates responsiveness to acetylsalicylic acid,
- wherein the presence of thymine or adenine at position chromosome 6:160880877 indicates non-responsiveness to acetylsalicylic acid;
- and
- (b) administering acetylsalicylic acid to a human subject responsive to acetylsalicylic acid to reduce the risk of a cardiovascular event, or
- administering an antiplatelet or antithrombotic agent that is not acetylsalicylic acid to a human subject non-responsive to acetylsalicylic acid to reduce the risk of a cardiovascular event.
4 more elements
A method of treatment comprising:
- selecting a human subject on the basis that the human subject has an Apo(a) polymorphism characterized by cytosine or guanine at chromosome 6:160880877 (March 2006 assembly—NCBI build 36.1;
- rs3798220 dbSNP @ NCBI), and
- administering to the human subject acetylsalicylic acid, thereby reducing the risk of a future cardiovascular event.
Dependencies are inferred from the claim text.